Table 4 Direct and indirect costs of insulin therapy in trial arms reported in USD
| Â | Â | Trial arms | ||
|---|---|---|---|---|
Type of cost | Subcategory | BIAsp 30 (n = 82) | NPH/Reg Insulin (n = 82) | P value |
Direct costs | Laboratory | 55.3 ± 12.9 | 51.1 ± 11.1 | 0.732 |
|  | Medications | 225.8 ± 41.7 | 60.5 ± 22.6 | 0.024 |
|  | Clinical visits | 55.9 ± 13.8 | 56.2 ± 9.3 | 0.815 |
|  | Inpatient | 235.4 ± 51.8 | 535.9 ± 37.8 | 0.009 |
|  | Non-medical | 17.7 ± 4.9 | 22.0 ± 4.2 | 0.332 |
Indirect costs | Productivity loss | 340.4 ± 42.2 | 375.4 ± 70.3 | 0.271 |
Total |  | 930.5 ± 81.4 | 1101.3 ± 165.5 | 0.004 |